ZESTRIL Drug Patent Profile
✉ Email this page to a colleague
When do Zestril patents expire, and when can generic versions of Zestril launch?
Zestril is a drug marketed by Twi Pharms and is included in one NDA.
The generic ingredient in ZESTRIL is lisinopril. There are twenty-one drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the lisinopril profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zestril
A generic version of ZESTRIL was approved as lisinopril by ASCENT PHARMS INC on July 1st, 2002.
Summary for ZESTRIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 81 |
| Clinical Trials: | 23 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ZESTRIL |
| Drug Sales Revenues: | Drug sales revenues for ZESTRIL |
| What excipients (inactive ingredients) are in ZESTRIL? | ZESTRIL excipients list |
| DailyMed Link: | ZESTRIL at DailyMed |
Recent Clinical Trials for ZESTRIL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pharmtechnology LLC | Phase 1 |
| ClinPharmInvest, LLC | Phase 1 |
| St. Jude Children's Research Hospital | Phase 2 |
Pharmacology for ZESTRIL
| Drug Class | Angiotensin Converting Enzyme Inhibitor |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ZESTRIL
US Patents and Regulatory Information for ZESTRIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-005 | Apr 29, 1993 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-003 | May 19, 1988 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-001 | May 19, 1988 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-002 | May 19, 1988 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-004 | May 19, 1988 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-006 | Jan 20, 1999 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZESTRIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-002 | May 19, 1988 | ⤷ Try a Trial | ⤷ Try a Trial |
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-003 | May 19, 1988 | ⤷ Try a Trial | ⤷ Try a Trial |
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-005 | Apr 29, 1993 | ⤷ Try a Trial | ⤷ Try a Trial |
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-004 | May 19, 1988 | ⤷ Try a Trial | ⤷ Try a Trial |
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-006 | Jan 20, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-001 | May 19, 1988 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZESTRIL
See the table below for patents covering ZESTRIL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 523579 | ⤷ Try a Trial | |
| Czechoslovakia | 237311 | PROCESSING OF CARBOXYALKYLDIPEPTIDE | ⤷ Try a Trial |
| Bulgaria | 39466 | METHOD FOR PREPARING OF CARBOXYALKYL DIPEPTIDES | ⤷ Try a Trial |
| South Africa | 7906688 | ⤷ Try a Trial | |
| Spain | 8101540 | ⤷ Try a Trial | |
| Netherlands | 930006 | ⤷ Try a Trial | |
| Zimbabwe | 24479 | AMINO ACID DERIVATIVES AS ANTIHYPERTENSIVES | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
